Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing–remitting MS

by Barro, C., Benkert, P., Chung, L., Daizadeh, N., Godin, J., Havari, E., Jacobs, A., Kaiser, C., Kappos, L., Kuhle, J., Leppert, D., Maceski, A., Michalak, Z., Mitchell, C.P, Rӧsch, N., Samad, T.A, Shankara, S., Sormani, M.P
Published 2022